Key Points
- Tempus AI COO Ryan Fukushima sold 5,000 shares on Jan. 5 at $64.26 for $321,300, reducing his stake by 3.25% to 148,808 shares (≈$9.56M); this sale is part of a series of insider disposals since early November totaling about 25,099 shares.
- Company fundamentals are mixed: Tempus reported Q revenue of $334.21M (+84.7% YoY) and beat EPS estimates (‑$0.11 vs. ‑$0.16) but remains unprofitable with a negative net margin and ROE, and carries a MarketBeat consensus rating of "Hold" with a $84 target.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $64.26, for a total value of $321,300.00. Following the completion of the transaction, the chief operating officer directly owned 148,808 shares of the company's stock, valued at $9,562,402.08. The trade was a 3.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Ryan Fukushima also recently made the following trade(s):
- On Monday, December 1st, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $75.72, for a total value of $378,600.00.
- On Tuesday, November 18th, Ryan Fukushima sold 10,099 shares of Tempus AI stock. The shares were sold at an average price of $65.54, for a total value of $661,888.46.
- On Monday, November 3rd, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $89.03, for a total value of $445,150.00.
Tempus AI Price Performance
Shares of NASDAQ TEM opened at $69.77 on Thursday. The stock has a market cap of $12.41 billion, a price-to-earnings ratio of -58.63 and a beta of 5.22. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32. The company's 50-day moving average price is $71.08 and its 200 day moving average price is $73.35. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.
Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million during the quarter, compared to analysts' expectations of $328.89 million. During the same quarter in the previous year, the business posted ($0.46) earnings per share. The firm's quarterly revenue was up 84.7% compared to the same quarter last year. As a group, research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.
Institutional Trading of Tempus AI
A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock worth $762,032,000 after acquiring an additional 1,706,837 shares during the period. Voloridge Investment Management LLC increased its position in Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock worth $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Tempus AI by 312.7% during the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock worth $102,869,000 after purchasing an additional 965,730 shares during the period. AQR Capital Management LLC purchased a new position in Tempus AI during the second quarter worth approximately $54,020,000. Finally, Clear Street Group Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at $57,821,000. 24.22% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
TEM has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price target on Tempus AI from $85.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, December 15th. Needham & Company LLC lifted their price objective on Tempus AI from $70.00 to $100.00 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. Canaccord Genuity Group reduced their target price on shares of Tempus AI from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, December 22nd. Morgan Stanley raised their price target on shares of Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a research note on Monday, December 1st. Finally, TD Cowen downgraded shares of Tempus AI from a "buy" rating to a "hold" rating and set a $88.00 price target for the company. in a report on Tuesday, October 21st. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tempus AI currently has a consensus rating of "Hold" and a consensus target price of $84.00.
Check Out Our Latest Analysis on Tempus AI
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
